Why endometrial cancer trial monitoring is increasingly important
Endometrial cancer is the most common gynecologic malignancy in the United States, and incidence is rising. The treatment landscape has undergone a fundamental shift with the approval of pembrolizumab for dMMR/MSI-H tumors and the HER2-targeted regimen trastuzumab deruxtecan (T-DXd) in HER2-positive serous endometrial cancer.
With over 52 trials active on ClinicalTrials.gov and 27 currently recruiting, key areas to monitor include:
- HER2-targeted ADC and bispecific trials in serous and clear cell histologies
- dMMR/MSI-H immunotherapy combinations and maintenance strategies
- POLE-ultramutated subtype trials — a molecularly distinct group with excellent prognosis
- FGFR2 inhibitor trials in FGFR2-amplified endometrial cancer
- CDK4/6 inhibitors in hormone receptor-positive endometrial cancer
- Novel ADCs targeting FOLR1, MSLN, and endometrial-specific antigens
Get daily endometrial cancer trial alerts
free 14-day trial, no credit card required. New trials and updates delivered to your inbox every morning.
Start Free — No Credit CardWhat we monitor for endometrial cancer
Configure a search profile for endometrial cancer with the following options:
- Condition keywords: "endometrial cancer", "uterine cancer", "endometrial carcinoma", "uterine serous carcinoma", "endometrioid adenocarcinoma"
- Phase filter: Phase 1 for early pipeline visibility, Phase 2/3 for registration-enabling trials
- Sponsor filter: Industry-sponsored only, or all including academic and NCI-funded trials
- Status filter: Recruiting only, or all active studies
Phase 3 endometrial cancer trials (2025–2026)
The 2026 endometrial Phase 3 pipeline is primarily ADC- and immunotherapy-driven. Key programs actively recruiting or completing enrollment:
| Drug / Program | Sponsor | Mechanism / Target | Population |
|---|---|---|---|
| Trastuzumab deruxtecan (T-DXd) | AstraZeneca / Daiichi | HER2-directed ADC (topo-I payload) | HER2-positive serous endometrial (approved + expansion) |
| Datopotamab deruxtecan (Dato-DXd) | AstraZeneca / Daiichi | TROP2-directed ADC (topo-I payload) | Advanced/recurrent endometrial (TROPION-EndoMet) |
| Pembrolizumab + lenvatinib | MSD / Eisai | PD-1 + VEGFR TKI combination | pMMR/MSS advanced endometrial (KEYNOTE-775, approved; label expansions ongoing) |
| Dostarlimab + carboplatin/paclitaxel | GSK | PD-1 + chemotherapy | Advanced primary endometrial (RUBY trial — dMMR/pMMR) |
| Sacituzumab tirumotecan (MK-2870) | MSD | TROP2-directed ADC | Endometrial cancer Phase 3 expansion programs (2025–2026) |
| Upifitamab rilsodotin (UpRi) | Sutro Biopharma / Pieris | FOLR1-directed ADC (auristatin payload) | FOLR1-positive advanced/recurrent endometrial cancer |
The endometrial cancer treatment landscape in 2026
HER2-targeted therapies reshaping serous histology
Trastuzumab deruxtecan (T-DXd) approval in HER2-positive advanced endometrial cancer opened a new targeted therapy opportunity in a subtype historically lacking effective options. The trial space is now active with follow-on studies examining T-DXd combinations, novel HER2 bispecifics, and next-generation HER2 ADCs. Monitoring these registrations is essential for companies positioning assets in the gynecologic oncology space.
dMMR immunotherapy — combinations and maintenance
Pembrolizumab's approval in dMMR endometrial cancer established the checkpoint inhibitor standard. The current generation of trials is testing dual checkpoint combinations (PD-1 + CTLA-4, PD-1 + LAG-3), maintenance strategies after first-line therapy, and biomarker refinement to identify who benefits most from immunotherapy. These trials represent the next competitive frontier in MSI-H endometrial cancer.
Molecular subtype-driven precision oncology
The TCGA classification — POLE-ultramutated, MSI-H/dMMR, copy-number high (serous-like), and copy-number low — is driving subtype-specific trial design. POLE-mutant endometrial cancer has extraordinary rates of response to immunotherapy, and dedicated trials are now quantifying this benefit. Companies with molecular diagnostic platforms are following these trials closely.
ADCs targeting gynecologic antigens
FOLR1 (folate receptor alpha) is highly expressed in endometrial cancer, making it an attractive ADC target. Multiple FOLR1 ADC programs are in clinical development alongside agents targeting mesothelin, MSLN, and other gynecologic cancer antigens. Several trials opened in 2025–2026 and are actively recruiting.
Who uses endometrial cancer trial monitoring
Gynecologic oncology pharma and biotech teams
Companies developing assets in gynecologic cancers track endometrial trial activity to understand the competitive landscape, identify partnership opportunities, and monitor competitor pipeline progress in relevant molecular subtypes.
Academic gynecologic oncologists
Physician-researchers monitor new trial registrations to inform their own study designs, identify NCCN or clinical trial network studies relevant to their patient populations, and stay current with emerging treatment paradigms.
Oncology nurses and patient advocates
Patients diagnosed with advanced endometrial cancer frequently seek clinical trial options. Healthcare providers and advocates tracking available trials can connect patients with relevant studies at institutions near them.
Ready to automate your endometrial cancer trial monitoring?
free 14-day trial — no credit card required. Setup takes under 2 minutes.
Get Free AlertsFrequently asked questions
How current is the endometrial cancer trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.
Can I track specific endometrial cancer subtypes separately?
Yes. On the Starter plan ($29/month), you can create up to 5 profiles. For example: one for HER2-positive endometrial trials, another for dMMR/MSI-H immunotherapy, and a third for all Phase 3 recruiting trials.
Does this cover uterine sarcoma trials as well?
Yes. Add keywords like "uterine leiomyosarcoma", "uterine sarcoma", or "carcinosarcoma" to your profile to capture those trials alongside endometrial carcinoma studies.
How is this different from ClinicalTrials.gov alerts?
ClinicalTrials.gov email alerts lack phase filtering, sponsor type filtering, and organized digest formatting. DataLookout delivers filtered, labeled alerts — the intelligence layer on top of the raw registry data.